Stockreport

U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syn...

Acceleron Pharma Inc.  (XLRN) 
Last acceleron pharma inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.acceleronpharma.com/investor-relations
PDF The FDA approval marks the second indication for Reblozyl and the first new treatment option in over a decade for patients with MDS who require red blood cell (RBC) tran [Read more]